Tsao

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares are having a good Monday after the company announced it's searching for a new CEO and that hedge fund activist Bill Ackman will join the board. Earlier in the morning, Barclays analyst Douglas Tsao downgraded the stock with a $34 price...